AUS
NZ
UK
CA
USA
IND
Highlights
- Knight Therapeutics' Mexican affiliate secures regulatory approval for Minjuvi® treatment.
- Minjuvi® targets relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
- The treatment offers a chemo-free option for patients ineligible for stem cell transplants.
Knight Therapeutics Inc. (TSX:GUD) is a specialty pharmaceutical company operating across the Americas, excluding the U.S. The company's focus includes developing and marketing treatments for various complex health conditions. One of its most recent advancements comes through its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V., which has achieved regulatory approval for a significant treatment option addressing relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Approval of Minjuvi® in Mexico
The regulatory approval granted by Mexico’s health regulatory body, COFEPRIS, allows for the use of Minjuvi® (tafasitamab) in combination with lenalidomide, followed by Minjuvi® monotherapy. This approval is aimed at adult patients with DLBCL who have either relapsed or have not responded to prior treatments and are ineligible for autologous stem cell transplantation (ASCT).
DLBCL is known as the most common type of non-Hodgkin lymphoma, with an aggressive clinical profile. While many patients respond to initial therapies, others face relapse or develop refractory disease, necessitating alternative treatment approaches. For these patients, Minjuvi® offers an innovative option, providing a targeted therapy aimed at addressing this challenging condition.
L-MIND Trial Results
The approval of Minjuvi® is backed by data from the L-MIND trial, an open-label, multicenter Phase 2 study that assessed the efficacy of the drug in combination with lenalidomide. The trial focused on adult patients with relapsed or refractory DLBCL who were not candidates for ASCT. The study provided promising results, indicating that Minjuvi® in combination with lenalidomide delivers substantial disease control, offering a chemo-free alternative for patients who have limited treatment options.
Role of Minjuvi® in DLBCL Treatment
Minjuvi® stands out due to its unique mechanism targeting CD19, a marker commonly expressed on the surface of B-cells. Its role in treating DLBCL is further emphasized by the 2024 National Comprehensive Cancer Network (NCCN) guidelines, which include Minjuvi® as a preferred option for patients who are not eligible for stem cell transplantation. The drug’s targeted immunotherapy approach represents a new era in treating patients who would otherwise face very few alternatives.
The addition of Minjuvi® to the range of therapies available for DLBCL patients marks a significant development in the management of this lymphoma subtype, particularly for those who cannot undergo stem cell transplantation.
